Quantification of frequent-hitter behavior based on historical high-throughput screening data

Future Medicinal Chemistry

Volumn 6, Issue 10, 2014, Pages 1113-1126

  Nissink, J Willem M ^a   Blackburn, Sam ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MANNICH BASE; PHOSPHOTRANSFERASE INHIBITOR; RHODANINE; STROMAL CELL DERIVED FACTOR 1;

ARTICLE; BEHAVIOR; CRYSTAL STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE RESULT; FOLLOW UP; HIGH THROUGHPUT SCREENING; LIMIT OF QUANTITATION; LIPOPHILICITY; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STRUCTURE ACTIVITY RELATION; UNCERTAINTY; ALGORITHM; DRUG DATABASE; DRUG DEVELOPMENT; HUMAN; PROCEDURES;

ALGORITHMS; DATABASES, PHARMACEUTICAL; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; UNCERTAINTY;

EID: 84905495972     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.72     Document Type: Article

References (31)

1. Macarron R, Banks MN, Bojanic D et al. Impact of highthroughput screening in biomedical research. Nat. Rev. Drug Discov. 10, 188-195 (2011
2. Mayr LM, Bojanic D. Novel trends in high-Throughput screening. Curr. Opin. Pharmacol. 9(5), 580-588 (2009
3. Mayr LM, Fuerst P. The future of high-Throughput screening. J. Biomol. Screen. 13, 443-448 (2008
4. Roche O, Schneider P, Zuegge J et al. Development of a virtual screening method for identification of 'frequent hitters' in compound libraries. J. Med. Chem. 45(1), 137-142 (2002
5. Baell JB, Holloway GA. New substructure filters for removal of pan-Assay interference compounds from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53, 2719-2740 (2010
6. Jadhav A, Ferreira RS, Klumpp C et al. Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J. Med. Chem. 53(1), 37-51 (2010
7. Baell JB. Observations on screening-based research and some concerning trends in the literature. Future Med. Chem. 2, 1529-1546 (2010
8. Habig M, Blechschmidt A, Dressler S et al. Efficient elimination of nonstoichiometric enzyme inhibitors from HTS hit lists. J. Biomol. Screen. 14(6), 679-689 (2009
9. Johnston PA, Soares KM, Shinde SN et al. Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. Assay Drug Dev. Technol. 6(4), 505-518. (2008
10. Bruns RF, Watson IA. Rules for identifying potentially reactive or promiscuous compounds. J. Med. Chem. 55, 9763-9772 (2012
11. Walters P, Namchuck M. Designing screens: How to make your hits a hit. Nat. Rev. Drug Discov. 2, 259-266 (2003
12. McGovern SL, Caselli E, Grigorieff N, Shoichet BKA. Common mechanism underlying promiscuous inhibitors from virtual and high-Throughput screening. J. Med. Chem. 45, 1712-1722 (2002
13. Sassano MF, Doak AK, Roth BL, Shoichet BK. Colloidal aggregation causes inhibition of G protein-coupled receptors. J. Med. Chem. 56(6), 2406-2414 (2013
14. Thorne N., Auld DS, Inglese J. Apparent activity in highthroughput screening: Origins of compound-dependent assay interference. Curr. Opin. Chem. Biol. 14(3), 315-324. (2010
15. Tukey J. Exploratory Data Analysis. Addison-Wesley Publishing Company, Reading, London, UK (1977
16. Jetter K, Depczynski U, Molt K, Niemöller A. Principles and applications of wavelet transformation to chemometrics. Anal. Chim. Acta 420, 169-180 (2000
17. Bardelle C, Boros J. Development of a high-content highthroughput screening assay for the discovery of ATM signaling inhibitors. J. Biomol. Screen. 17(7), 912-920 (2012
18. Wang Y, Xiao J, Suzek TO et al. PubChem's BioAssay database. Nucleic Acids Res. 40(1), D400-D412 (2012
19. Tarcsay A, Keserü GM. Contributions of molecular properties to drug promiscuity. J. Med. Chem. 56, 1789-1795 (2013
20. Bruneau P. Search for predictive generic model of aqueous solubility using bayesian neural nets. J. Chem. Inf. Comput. Sci. 41, 1605-1616 (2001
21. Advanced Chemical Development Inc. www.acdlabs.com
22. Bruneau P, McElroy NR. logD7.4 modeling using bayesian regularized neural networks. assessment and correction of the errors of prediction. J. Chem. Inf. Model. 46, 1379-1387 (2006
23. McLean LR, Zhang Y, Li H et al. Discovery of covalent inhibitors for MIF tautomerase via co-crystal structures with phantom hits from virtual screening. Bioorg. Med. Chem. Lett. 19, 6717-6220 (2009
24. Cardellicchio C, Capozzi MAM, Naso F. The Betti base: The awakening of a sleeping beauty. Tetrahedron Asymmetry 21, 507-517 (2010
25. Azizmohammadi M, Khoobi M, Ramazani A et al. 2H-chromene derivatives bearing thiazolidine-2, 4-dione, rhodanine or hydantoin moieties as potential anticancer agents. Eur. J. Med. Chem. 59, 15-22 (2013
26. Yin X, Giap C, Lazo JS, Prochownik EV. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 22, 6151-6159 (2003
27. Mendgen T, Steuer C, Klein CD. Privileged scaffolds or promiscuous binders: A comparative study on rhodanines and related heterocycles in medicinal chemistry. J. Med. Chem. 55(2), 743-753 (2012
28. Tomasic T, Masic LP. Rhodanine as a privileged scaffold in drug discovery. Curr. Med. Chem. 16(13), 1596-1629 (2009
29. Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc.) 41(12), 773-784 (2005
30. Lin X, Huang XP, Chen G et al. Life beyond kinases: Structurebased discovery of sorafenib as nanomolar antagonist of 5-HT receptors. J. Med. Chem. 55(12), 5749-5759 (2012
31. Whitty A. Growing PAINS in academic drug discovery. Future Med. Chem. 3(7), 797-801 (2011.